New research study utilizing RWD uncovers genetic associations in ME/CFS and long COVID

PrecisionLife and Metrodora Institute's MetX study uses real-world data to identify the genetic associations in ME/CFS and long COVID, aiming to advance personalized treatment options for these conditions.

PrecisionLife, a clinical-stage precision medicine company, and the Metrodora Institute, a leading healthcare center specializing in multisystem disorders, have announced the first results from their collaborative MetX study. This research represents a significant step forward in precision medicine for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID, conditions that affect millions of people worldwide but have historically been difficult to diagnose and treat.

Funded by a $1 million grant from the Metrodora Foundation, the MetX study leverages real-world data (RWD) and disease models developed by PrecisionLife. By analyzing patient data and genetic information, the study aims to uncover the underlying biological mechanisms of ME/CFS and long COVID. RWD plays a critical role in this effort by providing insights into how these diseases manifest and progress outside controlled clinical environments.

PrecisionLife’s DiseaseBank™, a repository of data from over 40 chronic disease studies, has been instrumental in this effort. Using advanced combinatorial analytics, DiseaseBank allows researchers to identify complex biological interactions that may otherwise go unnoticed. This approach helps stratify patients into clinically relevant subgroups based on shared disease mechanisms, allowing for the identification of hundreds of biomarkers and potential drug targets. These insights support both the discovery of new treatments and the repurposing of existing drugs, fostering the development of personalized therapies for chronic conditions.

“The speed and precision of our progress in these trials is remarkable,” said Steve Gardner, CEO of PrecisionLife. “We identified and published the first-ever replicated genetic associations in both ME/CFS and long COVID. Within six months, our partners at Metrodora Institute have designed, recruited, and returned the first research results for groundbreaking diagnostic tests incorporating our unique disease insights. We’re confident that the supporting systems and workflows are in place to support further trials and tests. Our partnership with Metrodora has the potential to transform the lives of tens of millions of patients affected by these and many other debilitating diseases.”

ME/CFS and long COVID are complex conditions that affect multiple biological systems, including neurological and immune functions. Despite ongoing research, their underlying mechanisms remain poorly understood, leading to diagnostic delays and limited treatment options. The economic impact of these diseases on healthcare systems worldwide is substantial.

The MetX study seeks to change this by providing participants with individualized reports that detail the mechanisms of their disease. These reports, based on a simple saliva test, offer a rapid assessment of a patient’s disease risk and underlying genetic factors. This information allows clinicians to make more precise diagnostic decisions and tailor treatments to the specific needs of each patient.

Amy Rochlin, Executive Director of the Metrodora Foundation, highlighted the significance of this initiative. “This study has the massive potential to unlock significant breakthroughs and deliver much-needed clarity in diagnosing and treating these complex diseases and revolutionizing care for countless individuals who currently have few effective options.”

Looking ahead, the study plans to expand recruitment to 1000 participants to further validate the new genotypic tests. These tests could also lay the foundation for future clinical trials evaluating repurposed drugs that target specific disease mechanisms. If successful, this precision medicine approach could improve patient outcomes and offer more effective treatments for ME/CFS, long COVID, and other chronic conditions.